Imagine trying to find a needle in a haystack, but the needle is a tiny molecule in your blood. Current tools often miss these markers because they are too few or the signal is too weak. This technology uses tiny 3D 'nanowires' that act like high-powered antennas to catch and amplify these signals, making them much easier to spot.
Current biomarker assays lack the sensitivity for multiplexing and have weak signal-to-noise ratios. Additionally, existing 3D nanowire platforms are too expensive and difficult to produce reproducibly at scale.
A beta production tool (ATXY) and a method to produce vertically aligned GaP and Si nanowires in polymer films on a large scale.
If you are a diagnostic lab provider dealing with late-stage cancer detection due to low biomarker concentrations — this project developed 3D NW-platforms that provide a 20-times increase in sensitivity. This allows for earlier diagnosis and improved patient survival rates.
If you are a device manufacturer dealing with the high cost of producing reproducible biosensors — this project developed Aerotaxy™ production technology. It enables mass-scale, cost-effective production of aligned nanowires for commercial viability.
If you are an R&D firm dealing with weak signal-to-noise ratios in multiplexed biomarker assays — this project developed sensors with optical waveguiding properties. This results in signals more than an order of magnitude higher than planar platforms.
The project utilizes proprietary Aerotaxy™ technology to ensure that nanowire sensors can be produced at a cost that makes mass-scale production feasible and low-priced.
Yes, the objective is to enable mass- and cost-effective production of nanowire sensors, specifically achieving vertical alignment of nanowires on a large scale.
The solution relies on three core patented technologies that allow for the production of high-quality nanowires with controlled diameters.
Based on available project data, these sensors offer 20 times higher sensitivity than current solutions in the market.
The project period ran from 2022-06-01 to 2024-09-30, with the goal of bridging the risk-gap to reach TRL9.
The project is led by a single Swedish SME, Aligned Bio AB. This 100% industry-led consortium indicates a strong focus on commercialization and direct market entry rather than academic exploration.
Contact Aligned Bio AB in Sweden regarding Aerotaxy™ licensing
Contact us to explore partnership opportunities with Aligned Bio AB
